Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.
The care of inflammatory bowel disease has changed considerably with the introduction of a number of immunosuppressants including anti-metabolite and anti-TNF therapies. While efficacious, these medications also carry important risks, notably the potential risk of lymphoma. This risk is one of the most worrisome for both patients and physicians. Our current knowledge is still evolving; however, our understanding of what risks these drugs carry, both individually and synergistically, is critical in allowing informed decision making. In this article, we will describe the known lymphoma risks of commonly used immunosuppressant medications in inflammatory bowel disease, with an emphasis on non-Hodgkin's lymphoma and hepatosplenic T-cell lymphoma.
Bewtra
Meenakshi
M
Division of Gastroenterology, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Lewis
James D
JD
D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008223:Lymphoma / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced; D016399:Lymphoma, T-Cell / Q000139:chemically induced; D018570:Risk Assessment; D012307:Risk Factors
D007166:Immunosuppressive Agents